Quantum-Si (NASDAQ: QSI) and Nvidia (NASDAQ: NVDA) have launched a new partnership to advance the development of a new proprietary proteomics platform.

Atossa Therapeutics (NASDAQ: ATOS) has released new clinical data from their Phase II trial for (Z)-Endoxifen.

PureTech Health (NASDAQ: PRTC) has announced that their founded entity Seaport Therapeutics has raised $225M USD in a Series B financing round.

Firefly Neuroscience (NASDAQ: AIFF) and Bright Mind Biosciences (NASDAQ: DRUG) are collaborating to leverage AI technology for clinical trial data evaluation.

PureTech Health (NASDAQ: PRTC) has received an official approval from the United States FDA for their novel therapeutic KarXT for schizophrenia treatment.

Clinical stage biopharmaceutical company BioAge Labs (NASDAQ: BIOA) has officially listed on the Nasdaq after successfully raising $198 million in their IPO.

Elon Musk’s brain computer interface company Neuralink has been awarded a Breakthrough Device designation by the United States FDA for their Blindsight device.

Pre-clinical blood cell therapy startup Safi Biotherapeutics has raised $5 million in seed funding led by prominent deep tech venture capital fund J2 Ventures.

MIRA Pharmaceuticals (NASDAQ: MIRA) has officially designated neuropathic pain as the initial and primary indication for their novel oral ketamine analogue.

Atossa Therapeutics (NASDAQ: ATOS) has officially dosed their first patient in their clinical trial partnership with Quantum Leap Healthcare Collaborative.